Mainz Biomed NV ( NASDAQ:MYNZ ) , the molecular genetics diagnostic company making a non-invasive blood-based screening test for early detection of pancreatic cancer, reported results from a feasibility study that could have widespread implications for the early detection of cancer.

MYNZ

<p>Mainz Biomed NV（纳斯达克代码：MYNZ），一家开发非侵入性血液筛查测试以早期检测胰腺癌的分子遗传诊断公司，报告了一项可行性研究的结果，该研究可能对癌症的早期检测产生广泛影响</p>

Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland

Mainz Biomed 更新：胰腺癌早期检测测试显示出前所未有的结果，公司准备在瑞士推出 ColoAlert